Financial Performance - Total product revenue for the year ended December 31, 2025, was $37.1 million, an increase of 4.1% compared to $35.6 million in 2024[250]. - Gross profit for 2025 was approximately $26.5 million, representing a gross margin of 71.5%, up from 69.9% in 2024[256]. - Loss from operations improved by 10.4% to approximately $14.7 million in 2025, compared to $16.5 million in 2024, driven by revenue growth and gross margin improvement[260]. - Research and development expenses decreased by 33.2% to approximately $5.1 million in 2025, down from $7.6 million in 2024, due to the completion of the STAR-T clinical trial[257]. - Selling, general and administrative expenses increased by 5% to approximately $35.6 million in 2025, primarily due to higher legal and regulatory costs[258]. - Net interest expense for 2025 was approximately $2.6 million, an increase from $1.4 million in 2024, due to interest incurred on the credit facility[261]. - Benefit from income taxes was approximately $0.4 million for 2025, down from $1.7 million in 2024, due to the utilization of the New Jersey Technology Business Tax Certificate Transfer Program[265]. Strategic Initiatives - The company initiated a strategic workforce and cost reduction plan, resulting in a restructuring charge of approximately $0.5 million in 2025[259]. - The company expects to reach operating cash flow break-even in the second half of 2026 following the strategic workforce and cost reduction plan[252]. - The company plans to file a new De Novo application for DrugSorb-ATR with the FDA, following an appeal meeting that affirmed no safety-related issues with the device[250]. - The company initiated a Strategic Workforce and Cost Reduction Plan, reducing its workforce by approximately 10% and expects to reach operating cash flow break-even in the second half of 2026[275]. Financial Position - As of December 31, 2025, current assets were approximately $20.6 million and current liabilities were approximately $9.7 million[266]. - As of December 31, 2025, the company had approximately $7.8 million in cash, which may not be sufficient to fund operations beyond the next twelve months[276]. - An effective shelf registration statement allows the company to raise up to $150 million, with approximately $149.7 million available as of December 31, 2025[267]. - The company entered into a Loan and Security Agreement with Avenue Capital Group for up to $20 million, with the first tranche of $15 million disbursed under specific conditions[268]. - The Amended Loan and Security Agreement provides access to an additional $2.5 million, with an extension of the interest-only period to December 31, 2026, subject to FDA approval[281]. Capital Raising Activities - The company raised $6.25 million from a rights offering, with proceeds used to satisfy a debt covenant and release $5 million of restricted cash[273]. - The Company raised aggregate gross proceeds of $6.25 million from the Rights Offering, with $5.4 million net of fees[287]. - Participants received Units comprising one share of common stock and two Right Warrants, with the potential to issue an additional 6.25 million shares upon exercise[287]. - Approximately 1.4 million Series A Right Warrants were exercised at an exercise price of $1.13 per warrant, generating an additional $1.6 million in gross proceeds[287]. - The expiration date of the Series B Right Warrants was extended from April 10, 2025, to June 10, 2025[287]. - The Series B Right Warrants expired worthless due to the 5-day volume weighted average price of Common Stock being below the minimum required price of $2.00[287]. Tax and Valuation Considerations - The Company evaluates uncertain tax positions based on estimates and assumptions, which may differ from actual results[289]. - The fair value of warrants is estimated using the Black-Scholes or Monte Carlo pricing models, requiring significant estimates regarding inputs[295]. - Changes in assumptions used for estimating the fair value of warrants could materially affect the financial statements[298]. - The Company recognizes interest and penalties related to uncertain tax positions as a component of income tax expense[291]. - Deferred tax assets are evaluated for valuation allowances based on expectations of future taxable income, which could impact financial statements[292]. Other Financial Metrics - The company reported a gain on foreign currency transactions of approximately $9.3 million in 2025, compared to a loss of $4.2 million in 2024, attributed to the increase in the Euro to U.S. dollar exchange rate[262]. - Loss on abandoned patents increased by approximately $0.2 million or 67.4%, totaling $0.6 million for the year ended December 31, 2025, compared to $0.3 million for 2024[264].

Group 1 - The article does not provide any relevant content regarding the company or industry [1]

Financial Data and Key Metrics Changes - Full year 2025 sales revenues increased by 4% to $37.1 million, representing record core product sales [5][15] - Gross margins reached 71% for the full year and improved to 74% in Q4 2025, driven by manufacturing efficiencies [7][17] - Operating loss for 2025 improved by 10% to $14.7 million compared to $16.5 million in 2024 [16] - Adjusted net loss for 2025 was $14.2 million or $0.23 per share, compared to an adjusted net loss of $12.7 million or $0.23 per share in 2024 [17] Business Line Data and Key Metrics Changes - Direct sales outside of Germany increased by 13% to $8.6 million, while distributor sales grew by 11.4% to $16.5 million, together accounting for approximately 68% of total revenue [6][15] - Sales in Germany declined by 10% to $11.8 million, reflecting the near-term impact of restructuring efforts [6][15] Market Data and Key Metrics Changes - The company has delivered over 300,000 treatments globally across 70 countries, indicating a broad and growing clinical footprint [4] - Clinical evidence continues to drive adoption, with over 75% of surveyed physicians adopting blood purification, with CytoSorb being one of the most commonly used modalities [10] Company Strategy and Development Direction - The company is focused on driving sales growth outside of Germany while repositioning its operations in Germany for long-term success [5] - The PuriFi initiative aims to expand access and utilization of CytoSorb therapy without reliance on existing dialysis infrastructure [8] - DrugSorb-ATR represents a significant pipeline opportunity, with an estimated initial market opportunity of over $300 million, expanding to over $1 billion over time [12] Management's Comments on Operating Environment and Future Outlook - Management believes that the actions taken in 2025 have positioned the company well heading into 2026, with expectations for gradual and sustained improvement in Germany [5][21] - The company aims to achieve cash flow break-even in the second half of 2026, supported by operational improvements and cost structure adjustments [21][22] Other Important Information - The company has strengthened its balance sheet and lowered its cost structure, establishing a realistic path to cash flow breakeven in 2026 [23] - The STAR-T randomized controlled trial has been published, showing that DrugSorb-ATR was safe and reduces the severity of bleeding in high-risk CABG patients [13] Q&A Session Summary Question: FDA regulatory process and timelines - Management is in interactive discussions with the FDA to ensure alignment before submission, aiming to streamline the process [27][29] Question: Confidence in reaching consensus with the FDA - Management is cautiously optimistic about aligning with the FDA and is working to define additional details to avoid surprises [28][29] Question: Early signs of improvement in the German market - Management noted leadership changes and a proactive approach to market development, which are expected to yield predictable sales momentum [30][31] Question: Status of the restructuring in Germany - Management believes they are in the later innings of restructuring, with incremental improvements expected over time [38] Question: Gross margin expectations for 2026 - Management aims to maintain gross margins in the low 70% range, with potential for improvement depending on increased volumes [40] Question: PuriFi pump strategy and revenue model - The PuriFi pump is viewed as an investment strategy, similar to a printer cartridge model, with expectations for future disposable revenue growth [41][42] Question: Pathway to breakeven and necessary steps - Management highlighted cost reduction initiatives and improved production efficiencies as key factors in reaching breakeven [46][47] Question: De-risking steps for DrugSorb-ATR resubmission - Management is ensuring alignment with the FDA to avoid another denial and is taking a cautious approach to the submission process [48][49]

Financial Data and Key Metrics Changes - Full year 2025 sales revenues increased by 4% to $37.1 million, representing record core product sales [5][15] - Gross margins reached 71% for the full year and improved to 74% in Q4 2025, driven by manufacturing efficiencies [7][17] - Operating loss for 2025 improved by 10% to $14.7 million compared to $16.5 million in 2024 [16] - Adjusted net loss for 2025 was $14.2 million or $0.23 per share, compared to an adjusted net loss of $12.7 million or $0.23 per share in 2024 [19] Business Line Data and Key Metrics Changes - Direct sales outside of Germany increased by 13% to $8.6 million, while distributor sales grew by 11.4% to $16.5 million, together accounting for approximately 68% of total revenue [6][15] - Sales in Germany declined by 10% to $11.8 million, reflecting the near-term impact of restructuring efforts [6][15] Market Data and Key Metrics Changes - The company has delivered over 300,000 treatments globally across 70 countries, indicating a broad and growing clinical footprint [4] - Clinical evidence continues to drive adoption, with over 75% of surveyed physicians adopting blood purification, with CytoSorb being one of the most commonly used modalities [10] Company Strategy and Development Direction - The company is focused on driving sales growth outside of Germany while repositioning the German market for long-term success [5] - Key priorities include advancing DrugSorb-ATR through the FDA regulatory process and achieving cash flow break-even by the second half of 2026 [22][23] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about early signs of improvement in the German market and expects gradual and sustained improvement throughout 2026 [8][31] - The company aims to create meaningful long-term value through consistent revenue growth and a strong focus on clinical evidence [23] Other Important Information - The PuriFi pump is a strategic initiative aimed at expanding access and utilization, with over 100 units placed globally [8] - The company is working on a streamlined and targeted resubmission for DrugSorb-ATR following a previous denial, with no safety concerns raised by the FDA [12][48] Q&A Session Summary Question: FDA regulatory process and timelines - Management is in interactive discussions with the FDA to ensure alignment before submission, aiming to streamline the process [27][29] Question: Confidence in reaching consensus with the FDA - Management believes they are on a defined regulatory path and is working to ensure no surprises during the submission process [28][29] Question: Early signs of improvement in the German market - Management noted a leadership change and a proactive approach to market development, leading to increased engagement and pipeline activity [31] Question: Status of the restructuring in Germany - Management believes they are in the later innings of restructuring, with expectations for incremental improvement over time [38] Question: Future gross margin expectations - Management aims to maintain gross margins above 71% and is optimistic about potential improvements with increased volumes [40] Question: PuriFi pump revenue model - The PuriFi pump is seen as an investment strategy, similar to a printer cartridge model, with expectations for future disposable revenue growth [41][42] Question: Pathway to operating break-even - Management is implementing cost reduction initiatives and expects to achieve cash flow break-even in the second half of 2026 [46][47] Question: De-risking steps for DrugSorb-ATR resubmission - Management is ensuring alignment with the FDA to avoid surprises and is taking a cautious approach to the resubmission process [48][49]

Financial Performance - 2025 revenue was $37.1 million, a 4% increase from $35.6 million in 2024, with a gross margin of 71%[5] - Operating loss improved by 10% to $14.7 million in 2025 compared to $16.5 million in 2024, while net loss decreased to $8.2 million or $0.13 per share from $20.7 million or $0.38 per share in 2024[6] - Adjusted EBITDA loss improved to $10.5 million in 2025 from $11.5 million in 2024[6] - Revenue for the three months ended December 31, 2025, was $9,234 million, a 0.9% increase from $9,150 million in the same period of 2024[47] - Gross profit for the year ended December 31, 2025, reached $26,491 million, up from $24,887 million in 2024, reflecting an 6.4% increase[47] - The net loss for the year ended December 31, 2025, was $8,198 million, a significant improvement compared to a net loss of $20,719 million in 2024[47] - Basic net loss per common share improved to $(0.13) for the year ended December 31, 2025, compared to $(0.38) in 2024[50] - Adjusted EBITDA for the year ended December 31, 2025, was $(10,537) million, compared to $(11,456) million in 2024, indicating a narrowing loss[50] Sales and Market Performance - Direct sales outside of Germany increased by 13% to $8.6 million, while distributor sales rose by 11.4% to $16.5 million, together accounting for approximately 68% of total sales[8] - By the end of 2025, over 300,000 cumulative CytoSorb® treatments were delivered globally, marking a more than 50% increase over the past few years[9] - The company reported a current U.S. market share of approximately 50% for ticagrelor, expected to increase significantly due to the availability of lower-cost generics[25] - CytoSorb has been used in over 300,000 devices cumulatively across more than 70 countries[37] Research and Development - The FDA confirmed no safety concerns regarding DrugSorb-ATR but upheld its denial for the initial De Novo application, citing the need for additional information[20] - A new De Novo application for DrugSorb-ATR is being prepared, incorporating real-world data from the STAR Registry to support a favorable benefit-to-risk profile[20] - The company is focused on advancing FDA De Novo authorization for DrugSorb-ATR to establish a second engine of revenue growth[32] - The company has received two FDA Breakthrough Device Designations for DrugSorb-ATR, targeting the removal of blood thinners during urgent cardiothoracic surgery[38] Cash and Assets - Total cash, cash equivalents, and restricted cash amounted to $7.8 million as of December 31, 2025, down from $9.1 million on September 30, 2025[10] - The company ended 2025 with a positive cash balance of $7.8 million, supported by a rights warrant offering and a credit facility amendment providing an additional $2.5 million in liquidity[27] - The company anticipates achieving cash flow breakeven in the second half of 2026 while maintaining adequate cash balances[30] - The company ended 2025 with total current assets of $20.634 million, a decrease from $21.604 million in 2024[44] - Total liabilities increased to $38.279 million in 2025 from $36.265 million in 2024[44] - The company reported an accumulated deficit of $312.207 million at the end of 2025, compared to $304.009 million in 2024[44] Operational Adjustments - In the fourth quarter of 2025, the company implemented a strategic workforce and cost reduction program, reducing headcount by 10%[29] - The company incurred restructuring costs of $510 million for the year ended December 31, 2025, reflecting ongoing strategic adjustments[47] - Research and development expenses decreased to $5,085 million for the year ended December 31, 2025, from $7,607 million in 2024, a reduction of 33.2%[47] Clinical Impact - CytoSorb therapy demonstrated significant clinical benefits, including improved hemodynamics and reduced mortality rates in various critical conditions[16] - The company plans to leverage clinical evidence to enhance user education and support sustained growth across all sales channels in 2026[18]

Core Insights - CytoSorbents Corporation reported a transitional year in 2025, achieving a revenue of $37.1 million, a 4% increase year-over-year, and a gross margin of 71% [3][4]. - The company is focused on achieving cash flow breakeven in the second half of 2026, supported by a strategic workforce and cost reduction program [2][26]. Financial Performance - Full-year revenue for 2025 was $37.1 million, up from $35.6 million in 2024, with a gross margin improvement from 70% to 71% [4]. - The operating loss improved by 10% to $14.7 million in 2025 compared to $16.5 million in 2024, while the net loss decreased to $8.2 million or $0.13 per share from $20.7 million or $0.38 per share in 2024 [4][24]. - In Q4 2025, revenue was $9.2 million, a 1% increase year-over-year, with a gross margin of 74% compared to 70% in Q4 2024 [4][5]. Business Highlights - The company has made significant progress in sales performance, with a 13% increase in direct sales outside Germany and an 11.4% increase in distributor sales, which together accounted for approximately 68% of total sales [5]. - CytoSorbents surpassed 300,000 cumulative CytoSorb treatments globally by the end of 2025, indicating broad adoption of its therapy across over 70 countries [6]. - The company is actively engaging with the FDA regarding a new De Novo application for DrugSorb-ATR, which aims to reduce serious perioperative bleeding in patients treated with blood thinners [15][17]. Clinical Momentum - New clinical data supports the use of CytoSorb in critical care, particularly for sepsis and septic shock, with significant reductions in inflammatory markers and improved patient outcomes reported in various studies [7][9]. - A recent multinational survey indicated that over 75% of physicians use extracorporeal blood purification primarily for refractory septic shock, with CytoSorb being the most preferred modality [9]. Regulatory Updates - The FDA confirmed no safety concerns regarding DrugSorb-ATR but required additional information for the proposed label indication, leading to a decision to submit a new De Novo application [17][18]. - The company anticipates a regulatory decision within a typical 150-day review period following the new submission [18]. Strategic Initiatives - The company implemented a strategic workforce and cost reduction program in Q4 2025, reducing headcount by 10% to lower expenses and realign operational spending [25]. - CytoSorbents aims to leverage clinical evidence to educate users on effective treatment strategies, which is expected to support sustained growth across all sales channels [14].

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Core Insights - CytoSorbents Corporation has launched HotSwap™, a new system designed to enhance the efficiency of blood purification therapy for critically ill patients, allowing for rapid and safe device exchanges during treatment [1][3][5] - The company has renewed its strategic partnership with Aferetica Srl in Italy, which has been instrumental in the adoption of CytoSorb technology in critical care and organ transplantation [2][3] - New clinical data presented at ISICEM 2026 supports the efficacy of CytoSorb therapy across various critical illnesses, reinforcing its role as a frontline treatment [4][5] Product Launch - HotSwap™ enables seamless exchange of CytoSorb adsorbers, improving treatment timing and reducing the workload on ICU staff [1][3] - The system facilitates the safe return of blood from used devices back to patients, which is crucial for maintaining blood volume during treatment [3] Partnership Renewal - The renewed agreement with Aferetica Srl extends a successful collaboration that has lasted over a decade, focusing on blood purification and organ preservation [2] - Both companies aim to continue expanding their innovations in blood purification and organ transplantation [2] Clinical Evidence - New clinical data presented at ISICEM includes findings from the COSMOS Registry, a Rhabdomyolysis Substudy, and a Meta-Analysis in COVID-19, highlighting the effectiveness of CytoSorb therapy [4][5] - Key outcomes from studies indicate significant improvements in patient survival rates and reductions in inflammatory markers, supporting the therapy's versatility in critical care [6][5]

Financial Results - Fourth quarter 2025 revenue is expected to be approximately $9.2 million, consistent with the fourth quarter of 2024 [5] - Full-year 2025 revenue is expected to be approximately $37.0 million, representing a growth of about 4% compared to $35.6 million for full-year 2024 [5] - Fourth quarter gross margin is expected to be in the range of 73% to 75%, an increase from 71% in the fourth quarter of 2024 and 70% in the third quarter of 2025 [5] - Full-year gross margin is expected to be approximately 72%, compared to 71% for full-year 2024 [5] Business Updates - The pivotal STAR-T study results for DrugSorb®-ATR have been accepted for publication in a top cardiac surgery journal, indicating the clinical relevance of the technology [4][5] - A Pre-Submission Meeting with the FDA is scheduled for this month to discuss the upcoming De Novo Application for DrugSorb®-ATR, with a filing expected by the end of Q1 2026 [4][5] - The company has surpassed 300,000 cumulative CytoSorb treatments worldwide, demonstrating the widespread use of its technology in critical care [6] Strategic Initiatives - The company amended its credit agreement to strengthen its balance sheet, adding $2.5 million in cash and extending the interest-only period through December 31, 2026 [5][6] - A strategic workforce and cost reduction program has been implemented, with expectations to achieve cash-flow breakeven (excluding restructuring payments) in the first quarter of 2026 [6] - Management will host in-person investor meetings during the J.P. Morgan Healthcare Conference in San Francisco [6]

Company Overview - CytoSorbents has made significant progress with two key products: CytoSorb, which removes harmful cytokines from the blood, and DrugSorb, which is designed to eliminate drugs, particularly blood thinners [2]. Industry Context - The biotechnology sector, particularly microcap companies like CytoSorbents, faces challenges due to the evolving regulatory landscape and the nascent nature of the science and technology involved [3]. Future Outlook - The company is preparing for key upcoming events that are crucial for investors to monitor, indicating a proactive approach to navigating the complexities of the biotechnology industry [3].